Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818991 | 1.00 | KEAP1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL21745161 | 1.00 | KEAP1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL21745167 | 1.00 | KEAP1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL21714032 | 1.00 | KEAP1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL21713612 | 0.92 | KEAP1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL21713916 | 0.90 | CA12 (0.32) | KEAP1NFE2L2 | |
| SCHEMBL29819155 | 0.87 | CA12 (0.33) | KEAP1 | |
| SCHEMBL21713401 | 0.87 | CA12 (0.33) | KEAP1 | |
| SCHEMBL31305931 | 0.84 | CA12 (0.32) | KEAP1 | |
| SCHEMBL26625670 | 0.84 | CA12 (0.32) | KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | KEAP1 1/4885NFE2L2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.